Objective. To consider the relevance of the duration of a clinical trial in ankylosing spondylitis: long-term (i.e. 1 yr) vs short-term (i.e. 6 weeks) assessment of a non-steroidal antiinflammatory drug (NSAID)-placebo controlled study.
few weeks, of these trials does not permit the sustained Paracetamol (500 mg per tablet) was used as analgesic rescue during the study. efficacy profile and the tolerability of these agents in this chronic disabling disease to be well documented Assessment criteria [15, 16 ] .
Clinical assessment was made at baseline and after 1, 3, These issues prompted us to conduct a placebo-6, 13, 26, 39 and 52 weeks of therapy by the same controlled study comparing the information obtained in investigator. The main evaluations were: (a) patient's the long term (i.e. 1 yr) vs the short term (i.e. 6 weeks) overall assessment of disease activity using a 100 mm concerning the efficacy and tolerability of two active VAS; (b) pain over the previous 2 days using a 100 mm NSAIDs (one of which has previously demonstrated its VAS; (c) functional disability using the Ankylosing efficacy in short-term placebo-controlled trial, i.e. piroxSpondylitis Functional Index (ASFI ) [22] ; (d) degree icam, and the other, i.e. meloxicam, which has demonof inflammation assessed by the latent period before strated a clinically acceptable efficacy/safety profile at a resolution of early morning stiffness (in minutes) and dose of 15 mg/day in rheumatoid arthritis [17] [18] [19] [20] .
the presence of sleep disturbances due to pain. Sleep impairment was measured using a four-grade scale in
Patients and methods which 1 = not bothered, no pain at all; 2 = bothered a little, pain is present part of the time, but mild in Patient population character; 3 = bothered a lot, steady or intermittent Out-patients fulfilling the modified New York criteria pain, which usually interferes with sleep; 4 = bothered for ankylosing spondylitis were recruited [21] . Other terribly, the night pain is constant, causes marked interdefined criteria for inclusion were: (a) daily NSAID ference with sleep and the patient is quite miserable (in intake during the month preceding the selection visit; this paper, sleep disturbance is considered when the (b) a wash-out period of NSAID of 2-15 days before recorded value was at least three); (e) range of motion the baseline visit; (c) a flare of the disease at baseline assessed by the Schober test and the chest expansion in defined by both pain evaluated on a 100 mm length centimetres. visual analogue scale ( VAS ) over 40 mm and an increase At each visit, the investigators checked for treatment in pain of at least 30% between the screening and the compliance and tolerability. Moreover, at entry, and at baseline visits.
weeks 6, 26 and 52 of the study, blood samples were Patients with peripheral articular disease, defined by collected to evaluate haematological, liver and renal the presence at the screening visit of an active (painful functions together with C-reactive protein (CRP) or swollen) peripheral arthritis (excluding hip and shouldetermination. der), and those with active inflammatory bowel disease, were excluded as were those with severe concomitant Sample size medical illness. Patients who had received corticosteroids
The sample size was calculated in order to demonstrate during the previous month and/or any slow-acting drug a statistically significant difference between an active initiated or with an altered dose during the previous 6 NSAID and the placebo during the first 6 weeks of the months were excluded.
trial. The changes in the ASFI, in pain and in overall assessment of disease activity during the trial were Study design chosen as the main assessment criteria prior to the The double-blind, placebo-controlled, dose-ranging study. For the variable ASFI, in a previous reported study of 1 yr duration was approved by the ethical study, the .. was estimated as 5.85 [23] . The clinically review board of each participating centre. The trial was relevant treatment difference was determined as three. conducted in different centres in four countries (Belgium, It was calculated that 103 patients per treatment group France, Germany and the UK ).
would demonstrate this difference when comparing each Study drugs active group to placebo with an overall a level of 0.05 ( leading to a∞ = 0.0167 for multiple treatment compariAfter confirming that the patient fulfilled the eligibility sons) and a power of at least 0.90 (two tailed ). The criteria defined above, patients were randomly assigned sample size calculation based on the expected changes to receive placebo, piroxicam 20 mg daily, meloxicam in overall disease activity assessment and pain gave 15 mg daily or meloxicam 22.5 mg daily. Patients similar results or even lower figures (data not shown). received two indistinguishable capsules each evening with a glass of water after food. Those in the placebo Statistical analysis group received two capsules of placebo, those in the The statistical analysis was conducted in order to evalupiroxicam 20 mg group one capsule of piroxicam 20 mg ate both the efficacy and the safety of the different and one of placebo, those in the meloxicam 15 mg group drugs, and also to assess the value of a 1 yr duration one capsule of placebo and one of meloxicam 15 mg, trial vs a 6 weeks trial. In terms of efficacy, the main while those in the 22.5 mg group received one capsule outcome measures were as follows. of meloxicam 7.5 mg and one of meloxicam 15 mg. The patients were asked to take the study drugs every day (a) Responders were defined as subjects in whom the relevant variable decreased by at least 50% during during 1 yr whatever the level of symptoms. Compliance was evaluated by pill count at each visit.
the study period and who did not have to discontinue the drug because of lack of efficacy during the study inclusion was the absence of an increase of at least 30% period. The variables included global assessment by of pain level between screening and baseline visit and/or the patient ( VAS ), pain ( VAS) and functional disabof <40 mm on pain ( VAS ) at baseline (56 patients). ility (ASFI ). Based on previous experience, we Table 1 summarizes patients' characteristics at the anticipated a 20% placebo effect and a 50% active start of the trial. There was no statistically significant drug effect after 6 weeks of therapy [4, 11] . difference in demographic data or clinical variables (b) The mean changes in all the studied variables during among the four groups, except for age, with a clinically the study period.
irrelevant lower mean age in the placebo group. Figure 1 (c) The time during which the patient stayed on study summarizes the study course. The main reasons for drug, without discontinuing it because of either lack discontinuation of the study drug were lack of efficacy of efficacy, toxicity or any reason. and adverse events. At week 6, 35 patients withdrew (13, 6, 10 and 6 in the placebo, piroxicam 20 mg, Outcome measures were evaluated on all patients meloxicam 15 mg and meloxicam 22.5 mg groups, entering the study (intention-to-treat analysis; ITT ) and respectively). also on those who continued treatment until the end of Therefore, 473 patients were included in the 6 week the study (completer analysis). In order to perform the and 1 yr ITT analysis and only 363 and 218 in the 6 ITT analysis, the LOCF (Last Observation Carried week and 1 yr completer analysis, respectively. Both Forward) technique was used.
The analyses were performed both after 6 weeks and analyses (ITT and completer) showed similar results in after 1 yr of follow-up.
the 6 week analysis. By contrast, in the placebo group, The statistical analysis used the following methods.
because of the high number of drop-outs, the results diverged at 1 yr between the two analyses. Herein, we 1. Baseline characteristics of the patients were compared present the ITT analyses. using a x2 test for nominal variables and a one-way analysis of variance for continuous variables.
Assessment of efficacy 2. The percentage of responders in each group was
Short-term (6 weeks) efficacy. The first step of the compared using Fisher's exact test.
analysis was to check our methodology by comparing 3. The mean changes in the continuous variables during the expected (see Patients and methods) and the the study were compared by treatment groups using observed results. For this purpose, the percentage of analysis of variance.
responders was calculated for all available patients who 4. Life table analyses (in which the event was defined entered the trial with a post-study drug available measas the discontinuation of the study drug) were perurement. Patients who withdrew from the study because formed. The four studied groups were evaluated using of lack of efficacy were considered as non-responders. the Kaplan-Meier technique and compared using the Table 2 shows the percentage of responders per treatlog rank test. ment subgroup. The percentages of responders with In order to evaluate each study drug (piroxicam and respect to pain assessment in the placebo group (26 out meloxicam), a P value of <0.0167 was considered as of 119, 22%) and in the piroxicam 20 mg group (52 out statistically significant (two tailed ) for primary end of 107, 49%) were close to those expected (20 and 50%, points (adjustment for multiple treatment comparisons). respectively). Moreover, the .. of the changes in the No adjustment was performed for secondary end points. functional index (from 5.7 to 6.6, see Table 3 ) and The second step consisted of the evaluation of the the mean treatment effect [differences in the mean discrepancies in the results obtained at week 6 and at changes of the functional index between an active treat-1 yr. For this purpose, we calculated and analysed the ment group and the placebo (from 3.0 to 4.0, see responder variables observed at week 6 and at 12 Table 3 )] were also close to those expected and premonths. For the continuous variables, the kappa intradefined (5.85 and 3.0, respectively) . The percentages of class coefficient of correlation was used as an index of responders in the meloxicam groups [62 out of 117 agreement between the mean changes observed at week (53%) and 60 out of 122 (49%) in the 15 and 22.5 mg 6 and 1 yr [24, 25] . Specifically, a value >0.75 is usually meloxicam groups, respectively] were statistically signiconsidered as excellent agreement and a value <0.40 as ficantly different from the placebo group (P = 0.001) poor agreement.
and very similar to the piroxicam 20 mg group. Table 3 Finally, we determined the value of a long-term shows the changes in each variable by the end of the systematic intake of NSAIDs by evaluating the efficacy 6 weeks. of the study drug between week 6 and week 52. For this, the outcome was the percentage of patients who
The latent period before the onset of activity of each did not have to discontinue the study drug because of NSAID group was estimated by analysis of two clinical inefficacy between week 6 and week 52.
variables (pain and functional disability) over time. This showed that all the active groups diverged from the placebo group after 1 week (data not shown).
Results

Long-term (1 yr) efficacy. The analyses after 1 yr Patients and study course
(conducted in a similar manner to those after 6 weeks of therapy) reached comparable results (see Tables 2  Of the 605 screened patients, 473 were included in the trial (see Fig. 1 ). The most frequent reason for nonand 3). In particular, there was a statistically significant aA responder was defined by a decrease of at least 50% in the evaluated variable and no discontinuation during the study period because of inefficacy.
bStatistical significance (P < 0.0167) when compared with placebo. cStatistical significance (P < 0.05) when compared with piroxicam. 19%) ]. However, the log rank test because of inefficacy shows a highly statistically signifidid not reach the level of statistical significance cant difference between placebo and each of the three (P = 0.08) (see Fig. 2b ). Upper gastrointestinal disactive groups without any difference between the three orders were the most common adverse events. The life active groups (Fig. 2a) . At the end of the study, 66 table analysis in which the event was defined by the (55%), 22 (20%), 28 (23%) and 20 (16%) patients occurrence of any upper gastrointestinal adverse event discontinued prematurely due to lack of efficacy in the during the 1 yr of the study showed a statistically placebo, piroxicam 20 mg, meloxicam 15 mg and meloxsignificant difference ( log rank test, P = 0.02) between icam 22.5 mg groups, respectively. The life table analysis the four study groups (13, 32, 18 and 20% in the in which the event was defined by the discontinuation placebo, piroxicam 20 mg, meloxicam 15 mg and meloxof the study drug whatever the reason for discontinuicam 22.5 mg groups, respectively). A statistically signiation showed similar results (highly statistically signifificant difference was only observed with piroxicam 20 mg cant difference between placebo and each of the three when compared to placebo (P = 0.004). The analysis active groups); moreover, there was also a statistically focused on the three active NSAID groups showed a significant (P < 0. Table 4 . The kappa index of agreement was 0.58, 0.65 group based on very suggestive clinical symptoms, but and 0.71 for pain, patient's global assessment and funcwithout endoscopic confirmation (patient's refusal ). tional index, respectively. Moreover, the kappa intra- Table 5 summarizes the adverse events observed in class coefficient of correlation between the changes the placeo and in the active NSAID groups as well as observed after 1 yr vs 6 weeks was 0.85, 0.87 and 0.83 the period of the first occurrence (week 0-week 6 vs for pain, patient's global assessment and functional week 6-week 52). This table shows that although most index, respectively. of the side-effects occurred during the first 6 weeks of The life table analysis focused on the subgroup of the the study, new additional side-effects were also reported 328 patients still taking the trial drug after week 6. between week 6 and 52. These appeared to be NSAID Outcome was defined by the discontinuation of the related since the percentage of gastrointestinal adverse study drug, due to lack of efficacy between week 6 and events increased in a higher proportion in the active week 52. The data reveal an inter-group statistically NSAID groups than in the placebo group. Indeed, the significant difference (P < 0.01, log rank test).
gastrointestinal NSAID effect can be estimated by the Compared to placebo, the relative risk of discontinudifferences in the percentage of gastrointestinal adverse ation of the study drug was statistically significantly events occurring in the NSAID and placebo groups. lower: 0.37 (P = 0.013) and 0.22 (P = 0.0001) for the During the first 6 weeks of the study, drug-related piroxicam 20 mg and meloxicam 22.5 mg, respectively, gastrointestinal adverse events were observed in 10 (9%) but did not reach statistical significance [0.64 (P = 0.17)] patients in the placebo group and in 62 (19%) in the for meloxicam 15 mg. There was no statistically signifi-NSAID group, i.e. a gastrointestinal NSAID effect of cant difference between piroxicam and both meloxicam 19 − 9 = 10%. The same approach applied in the groups. However, there was a statistically significant observed results at 1 yr shows that this gastrointestinal difference in favour of meloxicam 22.5 mg when comeffect is 11% (17 − 6%). This difference is due to the pared to meloxicam 15 mg (P = 0.01).
fact that more additional gastrointestinal adverse events Assessment of tolerability occurred in the NSAIDs group [40 (17%)] than in the placebo group [3 (6%) ] between week 6 and week 52, During the 1 yr of the trial, 159 patients experienced at i.e. a gastrointestinal NSAID effect of 11%. In this least one adverse event which was classified by the study, this is particular true with regard to the observed investigator as having a reasonable possibility that it gastro-duodenal ulcers in the piroxicam group (no ulcer was caused by the study drug, without any statistically significant difference between the different groups [32 during the first 6 weeks and 4 in the 6-52 week period). The main baseline characteristics of the studied Discussion patients are very similar to those previously reported in This placebo-controlled study suggests that a 1 yr trial other clinical and epidemiological studies of ankylosing may provide more data than a 6 week investigation, spondylitis. These results, together with the fact that the giving more information regarding both the efficacy and changes during the study in the main variables (i.e. pain, functional index and overall assessment of disease tolerability of NSAIDs in this condition.
T 4. Number of respondersa at 1 yr vs week 6 for the three chronic inflammatory disorder. Such an approach is selected outcome variables in the 473 ankylosing spondylitis patients frequently used to evaluate the long-term utility and/or efficacy of drugs in rheumatoid arthritis [26, 27] precisely the reason for discontinuation of a drug, the other proposed methodology is to evaluate the percentaA responder was defined as an improvement of at least 50% in the age of withdrawals over time whatever the reason for evaluated variable.
discontinuation. Using this methodology, we were able to detect a difference between active NSAIDs (in favour activity) in the inactive (placebo) and active (piroxicam) of meloxicam 22.5 mg when compared either to piroxgroups are similar to those expected, strengthen the icam 20 mg or to meloxicam 15 mg). These results validity of the trial.
suggest that, in some patients, a 22.5 mg meloxicam In terms of evaluation of the efficacy, and based on daily dose would be of more value than a 15 mg daily the data obtained in our study, it is interesting to dose during the painful flare of the disease and, conevaluate whether our conclusions might differ with the sequently, that a 52 week trial is useful to evaluate the duration of the study. The 6 week results on the primary efficacy of a new NSAID. Finally, one could consider outcome variables, i.e. mean changes or percentage that a short-term study (i.e. a 6 or even a 2 week study) responders in pain, patient's global assessment and is sufficient to confirm the efficacy of a new NSAID; at functional index, suggest that the three active groups variance, a longer duration study seems to be more (piroxicam 20 mg, meloxicam 15 mg and meloxicam appropriate to detect a difference between two active 22.5 mg) do not differ and, consequently, that meloxNSAIDs or between two different dosages of a given icam 15 mg could represent the optimal daily dosage to NSAID. be used in ankylosing spondylitis. Based on the 52 week
In terms of evaluation of the tolerability, it also seems results on the same parameters, the conclusions might interesting to evaluate whether our conclusions might be that most information obtained at 1 yr was in fact differ with the duration of the study. The detailed given at week 6 and, consequently, that a 52 week trial analysis of adverse events suggests that a 1 yr trial is of is useless to evaluate the efficacy of a new NSAID.
greater value than a 6 week one in order to define the However, the conclusions might be different if the tolerability of NSAIDs in ankylosing spondylitis. For outcome measure is not only focused on the convenexample, the gastrointestinal treatment effect, i.e. the tional ones (mean changes and percentage responders), differences in the percentages of observed gastrointesbut also on the percentage of patients still taking the tinal adverse events between active drugs and the plastudied drug over time.
cebo, was 10% at week 6 and 11% between week 6 and The life table analysis in which the event is defined year 1. These results clearly confirm that drug-related by the percentage of patients who have to discontinue gastrointestinal adverse events can occur after the first the study drug because of lack of efficacy might be more sensitive when applied to longer duration studies in this 6 weeks of the study [28] . The life table analysis evaluat-T 5. Number ( Kaplan-Meier product limit estimate as percentage) of patients with drug-related adverse events (AE) during the 1 yr of the study by treatment group and study period of the first occurrence (13) 71 (23) 8 (8) 49 (14) 2 (4) 31 (14) PUBs 0 (0) 6 (2) 0 (0) 2 (<1) 0 (0) 4 (2) Central and peripheral nervous system disorders 8 (9) 15 (5) 7 (9) 11 (3) 1 (2) 5 (2) Skin and appendages 4 (4) 14 (5) 4 (4) 10 (3) 1 (2) 5 (2) Respiratory system disorders 2 (2) 2 (<1) 1 (<1) 1 (1) 1 (2) 1 (<1)
PUB is perforation of ulcer, ulcer, bleeding of the upper gastrointestinal tract. All PUBs were confirmed by endoscopy, except one case in the piroxicam group due to patient refusal.
aOnly upper GI AE as referred terms known to be potentially related to NSAID toxicity were taken into account (PUB/gastritis/abdominal pain/dyspepsia/nausea/vomiting).
ing the percentage of patients suffering from an upper
